Lv4
464 积分 2023-10-17 加入
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
1个月前
已关闭
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD
1个月前
已完结
Rovadicitinib: First Approval
1个月前
已关闭
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
1个月前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
1个月前
已完结
Rovadicitinib: First Approval
1个月前
已关闭
Beyond suppression: the paradox of JAK inhibitors as amplifiers of cancer immunotherapy
1个月前
已完结
Enlonstobart: First Approval
4个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
4个月前
已完结
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
